Our passion, your health.

11/11/2016

HYMOVIS® Receives Permanent, Product-Specific J-Code from the Center for Medicare and Medicaid Services (CMS)

HYMOVIS® offers a convenient two-dose regimen

Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services (“CMS”) has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System (“HCPCS”) code, or J-Code.
The new J-Code provides reimbursement coding to healthcare professionals that administer HYMOVIS® and becomes effective on January 1, 2017.

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Fidia worldwide

Direct links to access Fidia’s international websites:


Follow us:

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- advanced wound care
- dermatology
- neurology
- dermo-aesthetics